What's on this Page
What is Tenapanor
Tenapanor is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for irritable bowel syndrome with constipation (IBS-C) in adults.
Tenapanor is minimally absorbed from the GI tract and acts locally to increase bowel movements and decrease abdominal pain. In clinical studies, tenapanor demonstrated a statistically significant reduction in constipation and abdominal pain in adults with IBS-C.
The primary endpoints were at least a 30% reduction in the weekly average abdominal pain score compared with baseline and an increase of at least 1 complete spontaneous bowel movement (CSBM) in weekly average from baseline, in the same week, for at least 6 of the first 12 treatment weeks. In both trials, patients receiving tenapanor met the primary endpoints (Trial 1: 37% versus 24% placebo, Trial 2: 27% versus 19% placebo).
Tenapanor carries a boxed warning for risk of serious dehydration in pediatric patients. Tenapanor was approved by the FDA in September 2019.
Brand Name
IBSRELA
Indications
- constipation
- irritable bowel syndrome
For the treatment of irritable bowel syndrome with constipation (IBS-C)
Side Effects
- abdominal pain
- dehydration
- diarrhea
- diarrhea
- dizziness
- flatulence
- GI bleeding
- hyperkalemia
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- abdominal pain
- breast-feeding
- children
- cholelithiasis
- Crohn’s disease
- diarrhea
- diverticulitis
- fecal impaction
- gastric cancer
- GI disease
- GI obstruction
- infants
- inflammatory bowel disease
- neonates
- pregnancy
Interactions
No information is available regarding drug interactions associated with Tenapanor
